Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease

International Journal of Colorectal Disease

Volumn 21, Issue 3, 2006, Pages 276-281

  Sorrentino, Dario ^a,b   Avellini, Claudio ^a   Beltrami, Carlo Alberto ^a   Pasqual, Enrico ^a   Zearo, Ester ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Colonic strictures; Crohn's disease; Infliximab

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT DISORDER; CASE REPORT; CELL INFILTRATION; CLINICAL FEATURE; CLINICAL TRIAL; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SELECTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTESTINAL FIBROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPTOM; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIBODIES, MONOCLONAL; COLONIC DISEASES; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA;

EID: 33244465400     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-005-0739-0     Document Type: Article

References (29)

1. Stenson WF (1999) Inflammatory bowel disease. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Yamada textbook of gastroenterology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1775-1839
2. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123:679-688
3. Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476-480
4. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J (2003) Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52:552-557
5. Geboes KP, Cabooter L, Geboes K (2000) Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastro-Enterol Belg 63:371-376
6. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122:512-530
7. Olaison G, Sjodahl R, Tagesson C (1990) Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not of endoscopically viewed inflammation. Gut 31:325-328
8. Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L (1995) Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 42:252-255
9. Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 10:55-60
10. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135
11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035
12. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116:22-28
13. Waetzig GH, Schreiber S (2004) Mechanisms of infliximab: The reverse side of a drug effect. Inflamm Bowel Dis 10:S38-S43
14. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 126:19-31
15. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116:1029-1034
16. Lichtenstein GR, Olson A, Bao W, Travers S, Diamond RH (2002) Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn's disease patients: Accent I study results. Am J Gastroenterol 97:S254
17. Keighley MR, Stockbrugger RW (2003) Inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 3):66-70
18. Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938-941
19. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R (1988) Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 94:257-265
20. Owens MW, Grisham MB (1993) Cytokines increase proliferation of human intestinal smooth muscle cells: Possible role in inflammation-induced stricture formation. Inflammation 17:481-487
21. Pucilowska JB, Williams KL, Lund PK (2000) Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: Cellular mediators and animal models. Am J Physiol 279:G653-G659
22. Zimmermann EM, Li L, Hou YT, Cannon M, Christman GM, Bitar KN (1997) IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am J Physiol 273:G875-G882
23. Radford-Smith G, Jewell DP (1996) Cytokines and inflammatory bowel disease. Baillière's Clin Gastroenterol 10:151-164
24. van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121:1242-1246
25. Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P (2001) BMBF competence network "Inflammatory Bowel disease". Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 16:1-11
26. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769
27. Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: Maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 17:31-37
28. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126:402-413
29. Assche GV (2001) Can we influence fibrosis in Crohn's disease? Acta Gastro-Enterol Belg 64:193-196